Hyperion Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology.
Hyperion is currently developing Ravicti™ (glycerol phenylbutyrate), formerly known as HPN-100, for both urea cycle disorders (UCD) and hepatic encephalopathy (HE).